RxDoctor Payments Data

Sallye Watkins, APRN

Family · Yukon, OKNPI 1487170593

Payments from drug & device makers

$3,668in general payments, 2019–2025

Across 202 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$565
  • Lilly USA, LLC$242
  • Axsome Therapeutics, Inc.$201
  • Boehringer Ingelheim$191
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • plus $1K from 26 others

What the payments were for

  • Food & beverage$3,668100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,668 in reported general payments places this provider in the 90th percentile of 2,026 family providers in Oklahoma.

See all family providers in Oklahoma

Medicare billing

Part B allowed, 2024
$25,966
Medicare patients
103
Services billed
830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin26$32,891
EliquisApixaban15$23,330
MounjaroTirzepatide16$20,352
OzempicSemaglutide17$18,226
FarxigaDapagliflozin Propanediol14$10,601
LinzessLinaclotide11$6,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$2,645
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,563
Omeprazole26$1,026
Montelukast Sodium30$981
Gabapentin44$692
Atorvastatin Calcium46$656
Albuterol Sulfate HfaAlbuterol Sulfate25$589
Divalproex Sodium19$478
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst26$470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$191$32,89126 claims
PfizerEliquis$136$23,33015 claims
Lilly USA, LLCMounjaro, Olanzapine$242$20,64630 claims
Novo NordiskOzempic$32$18,22617 claims
AstraZenecaFarxiga$27$10,60114 claims
AbbVieLinzess$1,087$6,02211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,026 family providers in Oklahoma.

Other family in Yukon

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →